aspirin has been researched along with vorapaxar in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (11.54) | 29.6817 |
| 2010's | 21 (80.77) | 24.3611 |
| 2020's | 2 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Angiolillo, DJ; Guzman, LA | 1 |
| Moliterno, DJ | 1 |
| Butt, M; Lip, GY; Shantsila, E; Siddique, A | 1 |
| Goto, S; Ikeda, Y; Jensen, P; Kato, K; Yamaguchi, H; Yamaguchi, T | 1 |
| Diener, HC; Weber, R | 1 |
| Pollack, CV | 1 |
| Ağırbaşlı, M; Cinçin, A; Güvenç, H | 1 |
| White, HD | 1 |
| Angiolillo, DJ; Tello-Montoliu, A; Tomasello, SD; Ueno, M | 1 |
| Leonardi, S; Mahaffey, KW; Tricoci, P | 1 |
| Becker, RC; Chen, E; Cornel, JH; Dery, JP; Harrington, RA; Hord, E; Huber, K; Jennings, LK; Judge, HM; Kotha, J; Mahaffey, KW; Moccetti, T; Moliterno, DJ; Rorick, TL; Smyth, SS; Storey, RF; Strony, J; Thomas, GS; Tricoci, P; Valgimigli, M | 1 |
| Armstrong, PW; Aylward, PE; Chen, E; Harrington, RA; Held, C; Huang, Z; Jennings, LK; Leonardi, S; Mahaffey, KW; Moliterno, DJ; Rorick, T; Storey, RF; Strony, J; Tricoci, P; Van de Werf, F; Wallentin, L; White, HD | 1 |
| Anderson, JL; Bates, ER; Bode, C; Granger, CB; Huber, K; Kristensen, SD; Lopez Sendon, JL; Ohman, EM; Steg, PG; Tubaro, M; Valgimigli, M; Wallentin, L | 1 |
| Cai, TQ; Chintala, M; Forrest, M; Handt, L; Michener, MS; Raubertas, R; Seiffert, D; Sitko, G; Wickham, LA | 1 |
| Serebruany, VL | 1 |
| Arif, SA; D'Souza, J; Gil, M; Gim, S | 1 |
| Akins, S; Bhal, V; Dixon, M; Herr, MJ; Hord, E; Jennings, LK; Kotha, J; Seiffert, D; White, MM | 1 |
| Cabrera-Fuentes, HA; Cherepanov, V; Kim, MH; Serebruany, VL | 1 |
| Fortmann, SD; Kim, MH; Serebruany, VL | 1 |
| Can, M; Fortmann, SD; Hanley, DF; Kim, MH; Lordkipanidze, M; Marciniak, TA; Rao, SV; Serebruany, VL; Tanguay, JF | 1 |
| Bekbossynova, M; Cattaneo, M; Golukhova, E; Kim, MH; Marciniak, TA; Pya, Y; Serebruany, VL | 1 |
| Bash, LD; Davies, G; Du, M; Oguz, M; Ozer-Stillman, I; Whalen, JD | 1 |
| Anderson, MS; Chappell, DL; Gheyas, F; Gilmartin, JH; Horrow, JC; Kraft, WK; Nagalla, S; Naik, UP; Walker, BM; Wrishko, RE; Zhang, S | 1 |
| Chase, M; Davies, G; Du, M; Oguz, M | 1 |
| Aedma, SK; Combs, WG; Gupta, R; Kluck, B; Lin, M; Mehta, A; Patel, NC; Ranchal, P; Shah, R; Singh, S; Vyas, AV | 1 |
| Blaha, V; Carazo, A; Hrubša, M; Javorská, L; Karlíčková, J; Konečný, L; Krčmová, LK; Matoušová, K; Mladěnka, P; Musil, F; Paclíková, M; Parvin, MS; Skořepa, P; Šmahelová, A | 1 |
14 review(s) available for aspirin and vorapaxar
| Article | Year |
|---|---|
Clinical overview of promising nonthienopyridine antiplatelet agents.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Humans; Lactones; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Thrombin; Ticagrelor | 2008 |
Advances in antiplatelet therapy for ACS and PCI.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Angina, Unstable; Aspirin; Blood Platelets; Cardiac Catheterization; Fibrinolytic Agents; Humans; Lactones; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pyridines; Treatment Outcome | 2008 |
New antiplatelet drugs: beyond aspirin and clopidogrel.
Topics: Adenosine; Adenosine Monophosphate; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Drug Design; Humans; Imines; Lactones; Naphthalenes; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propionates; Purinergic P2 Receptor Antagonists; Pyridines; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention.
Topics: Aspirin; Blood-Brain Barrier; Cilostazol; Clopidogrel; Dipyridamole; Drug Interactions; Drug Therapy, Combination; Humans; Lactones; Naphthalenes; Platelet Aggregation Inhibitors; Propionates; Pyridines; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke; Succinates; Tetrazoles; Thrombosis; Ticlopidine | 2010 |
[Novel agents in antiplatelet therapy].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
Antiplatelet therapy: thrombin receptor antagonists.
Topics: Aspirin; Blood Platelets; Humans; Imines; Lactones; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyridines; Receptors, Thrombin; Thrombosis | 2011 |
Promises of PAR-1 inhibition in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Female; Humans; Imines; Lactones; Male; Myocardial Ischemia; Platelet Activation; Platelet Aggregation Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Receptor, PAR-1; Recurrence; Treatment Outcome | 2012 |
Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Fondaparinux; Heparin; Hirudins; Humans; Lactones; Peptide Fragments; Peptides; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Recombinant Proteins; Thiophenes; Ticagrelor; Tirofiban; Tyrosine; Warfarin | 2014 |
Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease.
Topics: Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Half-Life; Hemorrhage; Humans; Lactones; Myocardial Infarction; Myocardial Ischemia; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Receptor, PAR-1; Secondary Prevention; Stroke; Thrombosis; Ticlopidine | 2015 |
Solid cancers after antiplatelet therapy: Confirmations, controversies, and challenges.
Topics: Adenosine; Animals; Anticarcinogenic Agents; Aspirin; Blood Platelets; Carcinogenicity Tests; Clopidogrel; Colonic Neoplasms; Drug Therapy, Combination; Female; Humans; Lactones; Male; Mice; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasms; Neoplasms, Experimental; Neoplastic Cells, Circulating; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Randomized Controlled Trials as Topic; Rivaroxaban; Sex Factors; Species Specificity; Ticagrelor; Ticlopidine; Time Factors | 2015 |
Vorapaxar and optimal aspirin dose: The FDA outlook.
Topics: Aspirin; Drug Approval; Humans; Lactones; Platelet Aggregation Inhibitors; Pyridines; Receptors, Thrombin; United States; United States Food and Drug Administration | 2016 |
Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulation.
Topics: Animals; Aspirin; Clopidogrel; Diplopia; Drug Approval; Eye; Humans; Lactones; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Receptor, PAR-1; Receptors, Proteinase-Activated; Ticlopidine; United States; United States Food and Drug Administration | 2016 |
Protease-Activated Receptor Antagonist for Reducing Cardiovascular Events - A Review on Vorapaxar.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Receptors, Proteinase-Activated; Stroke; Treatment Outcome | 2023 |
Sex-Related Differences in Platelet Aggregation: A Literature Review Supplemented with Local Data from a Group of Generally Healthy Individuals.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenosine Diphosphate; Arachidonic Acid; Aspirin; Blood Platelets; Female; Humans; Lactones; Male; Platelet Aggregation; Platelet Aggregation Inhibitors | 2023 |
4 trial(s) available for aspirin and vorapaxar
| Article | Year |
|---|---|
Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Double-Blind Method; Female; Heparin; Humans; Japan; Lactones; Male; Middle Aged; Placebos; Pyridines; Receptor, PAR-1; Ticlopidine | 2010 |
Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Blood Platelets; Cells, Cultured; Europe; Female; Follow-Up Studies; Humans; Inflammation Mediators; Lactones; Male; Middle Aged; North America; Platelet Aggregation; Pyridines; Receptor, PAR-1; Receptors, Thrombin | 2014 |
Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial).
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Aspirin; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Humans; Lactones; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyridines; Receptors, Thrombin; Treatment Outcome | 2014 |
Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects.
Topics: Adenosine Diphosphate; Adult; Arachidonic Acid; Aspirin; Bleeding Time; Blood Coagulation Tests; Drug Therapy, Combination; Female; Healthy Volunteers; Humans; Lactones; Male; Middle Aged; Platelet Aggregation; Pyridines; Receptors, Thrombin; Young Adult | 2016 |
8 other study(ies) available for aspirin and vorapaxar
| Article | Year |
|---|---|
Emerging oral antiplatelet therapies for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aspirin; Cardiology; Clopidogrel; Drug Therapy, Combination; Emergency Medicine; Hemorrhage; Hospitalists; Humans; Imines; Lactones; Patient Selection; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; Pyridines; Receptor, PAR-1; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Humans; Lactones; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Pyridines; Quinazolinones; Randomized Controlled Trials as Topic; Receptor, PAR-1; Sulfonamides; Ticagrelor; Ticlopidine | 2011 |
Platelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist.
Topics: Animals; Aspirin; Bleeding Time; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Lactones; Macaca fascicularis; Platelet Aggregation Inhibitors; Platelet Transfusion; Pyridines; Receptors, Thrombin; Ticlopidine | 2015 |
Redesigning TRACER trial after TRITON.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Evaluation; Drug Therapy, Combination; Hemorrhage; Humans; Lactones; Neoplasms; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Research Design; Ticlopidine | 2015 |
Platelet function recovery following exposure to triple anti-platelet inhibitors using an in vitro transfusion model.
Topics: Apoptosis Regulatory Proteins; Arachidonic Acid; Aspirin; Blood Platelets; Blood Transfusion; Clopidogrel; Flow Cytometry; Hemorrhage; Humans; Lactones; P-Selectin; Peptide Fragments; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Transfusion; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Proteinase-Activated; Receptors, Purinergic P2Y12; Ticlopidine | 2015 |
Continued vorapaxar versus withdrawed clopidogrel both on top of low dose aspirin in patients undergoing heart surgery: A call for randomized trial.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Female; Humans; Lactones; Male; Myocardial Infarction; Postoperative Hemorrhage; Pyridines; Survival Analysis; Ticlopidine; Treatment Outcome | 2016 |
A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction.
Topics: Aspirin; Cardiovascular System; Clopidogrel; Hemorrhage; Humans; Lactones; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyridines; Secondary Prevention; Stroke; Thrombosis; Ticlopidine; Treatment Outcome | 2016 |
State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease.
Topics: Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Lactones; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Pyridines; Quality of Life; Quality-Adjusted Life Years; Secondary Prevention; Stroke; Thrombosis; Ticlopidine | 2017 |